cobas HPV
Roche Molecular Systems, Inc. · Decision date Sep 19, 2025
What did the FDA approve?
FDA records P190028/S021 as a supplement to PMA P190028, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 19, 2025.
FDA approval order statement
cobas HPV for use on the cobas 5800/6800/8800 Systems (cobas HPV) is a qualitative in vitro test for the detection of high-risk Human Papillomavirus. This test detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 in the specimens listed below. Clinician-collected cervical specimens should be obtained using an endocervical brush/spatula or broom and placed in the ThinPrep Pap Test PreservCyt Solution. Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained. cobas HPV is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of individuals with a cervix to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Microbiology
- Decision date
- Sep 19, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P190028/S021
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- Decision code
- APPR
- Decision date
- Sep 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190028. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190028 · Original PMA
cobas HPV for use on the cobas 6800/8800 Systems
P190028/S020 · Related supplement
cobas HPV
P190028/S021 received
Application receipt date recorded by FDA.
P190028/S021 · FDA decision
Special (Immediate Track)
P190028/S022 · Related supplement
cobas HPV
P190028/S025 · Related supplement
cobas HPV
P190028/S024 · Related supplement
cobas HPV
P190028/S023 · Related supplement
cobas HPV
P190028/S026 · Related supplement
cobas HPV
Timeline entries are records held by MedtechLedger for P190028. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190028
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Roche Molecular Systems, Inc. | PMA approval | Apr 3, 2020 | FDA | |
cobas HPVP190028/S020 | Roche Molecular Systems, Inc. | PMA supplement | Aug 7, 2025 | FDA |
cobas HPVP190028/S022 | Roche Molecular Systems, Inc. | PMA supplement | Dec 31, 2025 | FDA |
cobas HPVP190028/S025 | Roche Molecular Systems, Inc. | PMA supplement | Mar 17, 2026 | FDA |
cobas HPVP190028/S024 | Roche Molecular Systems, Inc. | PMA supplement | Apr 23, 2026 | FDA |
cobas HPVP190028/S023 | Roche Molecular Systems, Inc. | PMA supplement | Jun 16, 2026 | FDA |
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| Becton Dickinson and Company | PMA supplement | Aug 19, 2026 | FDA | |
BD Onclarity HPV AssayP160037/S028 | Becton Dickinson and Company | PMA supplement | Aug 14, 2026 | FDA |
Alinity m HR HPVP230003/S015 | Abbott Molecular, Inc. | PMA supplement | Jul 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P190028/S021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




